Indivior Pharmaceuticals, Inc. Diluted Shares Outstanding (Weighted Average)
Indivior Pharmaceuticals, Inc. (INDV) reported Diluted Shares Outstanding (Weighted Average) of 124.00 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding · last filed 2026-08-03
- Indivior Pharmaceuticals, Inc. weighted average number of shares outstanding, diluted for the quarter ending 2026-06-30 was 124.00M shares, a 1.59% decline year-over-year.
- Indivior Pharmaceuticals, Inc. weighted average number of shares outstanding, diluted for the quarter ending 2026-03-31 was 129.00M shares, a 3.20% increase year-over-year.
- Indivior Pharmaceuticals, Inc. weighted average number of shares outstanding, diluted for the quarter ending 2025-12-31 was 131.00M shares, a 0.77% increase year-over-year.
- Indivior Pharmaceuticals, Inc. weighted average number of shares outstanding, diluted for the quarter ending 2025-09-30 was 129.00M shares, a 3.01% decline year-over-year.
- Indivior Pharmaceuticals, Inc. weighted average number of shares outstanding, diluted for fiscal 2025 was 128.00M shares, a 3.76% decline from fiscal 2024.
- Indivior Pharmaceuticals, Inc. weighted average number of shares outstanding, diluted for fiscal 2024 was 133.00M shares, a 2.92% decline from fiscal 2023.
- Indivior Pharmaceuticals, Inc. weighted average number of shares outstanding, diluted for fiscal 2023 was 137.00M shares, a 1.44% decline from fiscal 2022.
- Indivior Pharmaceuticals, Inc. weighted average number of shares outstanding, diluted for fiscal 2022 was 139.00M shares.
| Period end | Weighted Average Number of Shares Outstanding, Diluted 3 month | Weighted Average Number of Shares Outstanding, Diluted 6 month | Weighted Average Number of Shares Outstanding, Diluted 9 month | Weighted Average Number of Shares Outstanding, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | 124.00M shares 10-Q · filed 2026-08-03 | 127.00M shares 10-Q · filed 2026-08-03 | 128.00M shares derived: average of 3 quarters · filed 2026-08-03 | 128.25M shares derived: average of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | 129.00M shares 10-Q · filed 2026-04-30 | 130.00M shares derived: average of 2 quarters · filed 2026-04-30 | 129.67M shares derived: average of 3 quarters · filed 2026-04-30 | 128.75M shares derived: average of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | 131.00M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 130.00M shares derived: average of 2 quarters · filed 2026-02-26 | 128.67M shares derived: average of 3 quarters · filed 2026-08-03 | 128.00M shares 10-K · filed 2026-02-26 |
| 2025-09-30 | 129.00M shares 10-Q · filed 2025-10-30 | 127.50M shares derived: average of 2 quarters · filed 2026-08-03 | 127.00M shares 10-Q · filed 2025-10-30 | 127.50M shares derived: average of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | 126.00M shares 10-Q · filed 2026-08-03 | 125.00M shares 10-Q · filed 2026-08-03 | 127.00M shares derived: average of 3 quarters · filed 2026-08-03 | 128.50M shares derived: average of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | 125.00M shares 10-Q · filed 2026-04-30 | 127.50M shares derived: average of 2 quarters · filed 2026-04-30 | 129.33M shares derived: average of 3 quarters · filed 2026-04-30 | 130.75M shares derived: average of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | 130.00M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 131.50M shares derived: average of 2 quarters · filed 2026-02-26 | 132.67M shares derived: average of 3 quarters · filed 2026-02-26 | 133.00M shares 10-K · filed 2026-02-26 |
| 2024-09-30 | 133.00M shares 10-Q · filed 2025-10-30 | 134.00M shares derived: average of 2 quarters · filed 2025-10-30 | 134.00M shares 10-Q · filed 2025-10-30 | |
| 2024-06-30 | 135.00M shares 10-Q · filed 2025-07-31 | 135.00M shares 10-Q · filed 2025-07-31 | ||
| 2024-03-31 | 137.00M shares 10-Q · filed 2025-05-01 | |||
| 2023-12-31 | 137.00M shares 10-K · filed 2026-02-26 | |||
| 2022-12-31 | 139.00M shares 10-K · filed 2025-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |